Evidence map›Paper›PMID 25680181›Full record

ArticlePloS one2015

Akacid medical formulation induces apoptosis in myeloid and lymphatic leukemic cell lines in vitro and in vivo.

Hannes Neuwirt, Elisabeth Wabnig, Clemens Feistritzer, Iris E Eder, Christina Salvador, Martin Puhr, Zoran Culig, Petra Massoner, Martin Tiefenthaler, Michael Steurer and 1 more

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hannes NeuwirtDepartment of Internal Medicine IV, Medical University of Innsbruck, Innsbruck, Austria.
Elisabeth WabnigDepartment of Internal Medicine IV, Medical University of Innsbruck, Innsbruck, Austria.
Clemens FeistritzerDepartment of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Austria.
Iris E EderDepartment of Experimental Urology, Medical University of Innsbruck, Innsbruck, Austria.
Christina SalvadorDepartment of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria.
Martin PuhrDepartment of Experimental Urology, Medical University of Innsbruck, Innsbruck, Austria.
Zoran CuligDepartment of Experimental Urology, Medical University of Innsbruck, Innsbruck, Austria.
Petra MassonerDepartment of Experimental Urology, Medical University of Innsbruck, Innsbruck, Austria.
Martin TiefenthalerDepartment of Internal Medicine IV, Medical University of Innsbruck, Innsbruck, Austria.
Michael SteurerDepartment of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Austria.
Guenther KonwalinkaDepartment of Internal Medicine I, Medical University of Innsbruck, Innsbruck, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Akacid medical formulation (AMF) is an oligoguanidine that exerts biocidal activity against airborne and surface microorganisms including bacteria, viruses, fungi, and molds, while showing relatively low toxicity to humans. We have previously shown that AMF exerts antiproliferative effects on a variety of solid tumor cell lines. In this study we raised the question whether AMF could also substantially inhibit cell growth or induce apoptosis in cell lines derived from hematologic malignancies such as leukemia or lymphoma. We found that AMF has antiproliferative effects on various hematologic cell lines derived from human leukemia and lymphoma. Additionally, we show that AMF induces apoptosis in leukemia cell lines not only via the extrinsic and intrinsic pathway, but also in a caspase-independent manner. This effect was found also in G0-arrested cells. Finally, in our animal experiments utilizing male nu/nu Balb/c mice we found a significant growth retardation, which was immunohistochemically associated with a significantly lower number of KI67-positive cells and caspase-3 induction in AMF-treated mice.

Indexed as

AnimalsAntineoplastic AgentsApoptosisCaspase InhibitorsCaspasesCell Line, TumorCell ProliferationDisease Models, AnimalEnzyme ActivationG1 Phase Cell Cycle CheckpointsGuanidinesHumansLeukemia, LymphoidLeukemia, MyeloidMaleMiceAkacid-medical-formulationAntineoplastic AgentsCaspase InhibitorsCaspasesGuanidinesProto-Oncogene Proteins c-bcl-2

Identifiers

PMID25680181
PMCPMC4334520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.